N/A N=56

Macrophage Phagocytosis in COPD

Chronic Obstructive Pulmonary Disease · Emphysema · Chronic Bronchitis

Bottom Line

View on ClinicalTrials.gov: NCT00298389 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2019

Primary outcome: Primary: Phagocytosis of H. Influenzae Concentration — 0.042; 0.042; 0.014; 0.06 relative fluorescence unit — p=0.05

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 21+ yrs
Sex: All
Sponsor: Imperial College London
Primary completion: Dec 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Phagocytosis of H. Influenzae Concentration	0.042; 0.042; 0.014; 0.06; 0.059; 0.025	0.05
PRIMARY Phagocytosis of S. Pneumoniae Concentration	0.066; 0.056; 0.012; 0.077; 0.072; 0.022	0.05

Summary

Patients with chronic obstructive pulmonary disease (COPD) that have frequent chest infections are the patients most likely to become worse over time. Why these people are more susceptible to chest infections is not known. One reason might be that the white cells in their lungs called macrophages do not work properly. Normally, these cells remove all the debris inhaled into the lung. This can also include bacteria. In patients with COPD, these macrophages are not able to remove these particles. The research question addresses why this happens

Eligibility Criteria

Inclusion Criteria

Healthy non-smoking subjects:

All normal volunteers will meet the following criteria:

Age 21-75 years. No history of respiratory or allergic disease. Normal baseline spirometry as predicted for age, sex and height. Non-smokers. No history of upper respiratory tract infection in the preceding six weeks. Not taking regular medication

COPD subjects:

COPD is diagnosed according to American Thoracic Society, European Respiratory Society and British Thoracic Society guidelines by the doctors in Professor Barnes' COPD clinic.

All COPD volunteers will meet the following criteria:

Age between 35-75 years. A smoking history of at least 10 pack years. ( 1 pack year = 20 cigarettes per day for 1 year) FEV1:FVC ratio of <0.7, post-bronchodilator FEV1 of <85% predicted, reversibility with inhaled beta2-agonist of <15% of predicted FEV1: all three criteria are required.

Exclusion Criteria

Subjects will not included in this study if they meet any of the following exclusion criteria:

Clinically significant findings in the medical history or on physical examination other than those of COPD in the COPD group.

Pregnant women or mothers who are breastfeeding. Subjects who are unable to give informed consent.-

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00298389). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.